secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0001213900-23-051097
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Therapeutics CFO separation agreement provides $880K severance
---------------------------------------------------------------------

- CFO Jillian Thomsen's employment terminated June 16, 2023; transition period from April 17.
- Company to pay $880,000 lump sum severance, plus COBRA through June 30, 2024.
- Career transition services and IT equipment benefits included in agreement.
- Agreement contains standard release of claims and negative PTO balance waiver.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390023051097/0001213900-23-051097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390023051097/ea180833-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-051097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer